Articles

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multi-centre, phase II, randomized, controlled trial (MUKfive)

Cancer Institute, University College London, London
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds
Department of Immunology and Inflammation and The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London
Cardiff and Vale University Health Board, Cardiff
The Institute of Cancer Research, London, UK and The Royal Marsden Hospital NHS Foundation Trust, London
Department of Clinical Haematology, Oxford University Hospitals NHS Trust, Oxford
Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Leeds
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds
Department of Haematology, University Hospitals of Leicester NHS Trust, Leicester
The Clatterbridge Cancer Centre, Liverpool
Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham
Department of Haematology, St Bartholomew's Hospital, London
Department of Haematology, University College Hospital, London
The Institute of Cancer Research, London, UK and The Royal Marsden Hospital NHS Foundation Trust, London
Perlmutter Cancer Center, NYU Langone Health, New York
Perlmutter Cancer Center, NYU Langone Health, New York
Haematological Malignancy Diagnostic Service (HMDS), St James's University Hospital, Leeds
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds
Haematologica Early view Apr 29, 2021 https://doi.org/10.3324/haematol.2021.278399